Matt Gamber’s Biotech Newsletter

Matt Gamber’s Biotech Newsletter

About the Substack

Weekly posts on small and mid-cap biotech stocks. 100% independent and reader supported with no company sponsored content or hedge fund compensation of any kind. See free performance posts for more information. Not financial advice, for research purposes.

Free Subscription Benefits

• One free monthly post on performance

Paid Subcription Benefits

• One weekly paid post averaging 2,750+ words and multimedia
• Occasional bonus posts when major breaking news happens in my coverage spectrum
• Subscriber chat and e-mail access

Paid Subscription Plans

• $100 a year
• $10 a month

About Matt Gamber